+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biotherapeutics Cell Line Development: Global Strategic Business Report

  • PDF Icon

    Report

  • 179 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309862

Quick Summary:

In a rapidly expanding healthcare sector, understanding the dynamics of the Biotherapeutics Cell Line Development Market is crucial for any forward-thinking business decision maker. This detailed report, projected to see a global scale valuation reaching up to US$135.2 million by 2030, provides in-depth insights into this thriving market that could equip your company with the knowledge it needs to stay competitive in your industry, and capitalize on potential growth areas.

The market's financial potential is significant, with the U.S alone expected to account for $25.2 million in 2022, while China's market is predicted to increase at a CAGR of 5.6% until 2030. Highlighting established and emerging markets, this report offers an essential comparative analysis. You will gain access to exclusive data on competitive companies, their market shares, and their geographical presence, enabling your business to strategize effectively, capitalize on new trends, and navigate potential challenges in the global Biotherapeutics Cell Line Development sector.

Global Biotherapeutics Cell Line Development Market to Reach $135.2 Million by 2030

The global market for Biotherapeutics Cell Line Development estimated at US$83.4 Million in the year 2022, is projected to reach a revised size of US$135.2 Million by 2030, growing at a CAGR of 6.2% over the analysis period 2022-2030. Transfection & Selection, one of the segments analyzed in the report, is projected to record 7.9% CAGR and reach US$28.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Single Cell Cloning segment is readjusted to a revised 5.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $25.2 Million, While China is Forecast to Grow at 5.6% CAGR

The Biotherapeutics Cell Line Development market in the U.S. is estimated at US$25.2 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$23 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6% and 4.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Select Competitors (Total 11 Featured) -

  • AGC Biologics
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • EMD Millipore Corporation
  • Lonza Group Ltd.
  • MilliporeSigma
  • ProBioGen AG
  • Selexis SA
  • Sony Biotechnology Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and the publisher's Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Biotherapeutics Cell Line Development

What is the estimated value of the Global Market for Biotherapeutics Cell Line Development?

The Global Market for Biotherapeutics Cell Line Development was estimated to be valued at $83.4 Million in 2022.

What is the growth rate of the Global Market for Biotherapeutics Cell Line Development?

The growth rate of the Global Market for Biotherapeutics Cell Line Development is 6.2%, with an estimated value of $135.2 Million by 2030.

What is the forecasted size of the Global Market for Biotherapeutics Cell Line Development?

The Global Market for Biotherapeutics Cell Line Development is estimated to be worth $135.2 Million by 2030.

Who are the key companies in the Global Market for Biotherapeutics Cell Line Development?

Key companies in the Global Market for Biotherapeutics Cell Line Development include AGC Biologics, Beckman Coulter, Inc., Becton, Dickinson & Company, Boehringer Ingelheim International GmbH, Catalent, Inc., EMD Millipore Corporation, Lonza Group Ltd., MilliporeSigma, ProBioGen AG and Selexis SA.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Biotherapeutics Cell Line Development - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Biotherapeutics Cell Line Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Biotherapeutics Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Transfection & Selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Transfection & Selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Transfection & Selection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Single Cell Cloning by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Single Cell Cloning by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Single Cell Cloning by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Biotherapeutics Cell Line Development Market Analysis of Annual Sales in US$ for Years 2014 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Biotherapeutics Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 11: USA Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 12: USA Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 13: USA 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • CANADA
  • Table 14: Canada Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 15: Canada Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 16: Canada 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • JAPAN
  • Biotherapeutics Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 17: Japan Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 18: Japan Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 19: Japan 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • CHINA
  • Biotherapeutics Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 20: China Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 21: China Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 22: China 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • EUROPE
  • Biotherapeutics Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 23: Europe Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
  • Table 24: Europe Historic Review for Biotherapeutics Cell Line Development by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 25: Europe 16-Year Perspective for Biotherapeutics Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 26: Europe Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 27: Europe Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 28: Europe 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • FRANCE
  • Biotherapeutics Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 29: France Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 30: France Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 31: France 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • GERMANY
  • Biotherapeutics Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 32: Germany Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 33: Germany Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 34: Germany 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • ITALY
  • Table 35: Italy Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 36: Italy Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 37: Italy 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Biotherapeutics Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 38: UK Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 39: UK Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 40: UK 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 41: Rest of Europe Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 42: Rest of Europe Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 43: Rest of Europe 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Biotherapeutics Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 44: Asia-Pacific Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 45: Asia-Pacific Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 46: Asia-Pacific 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
  • REST OF WORLD
  • Table 47: Rest of World Recent Past, Current & Future Analysis for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
  • Table 48: Rest of World Historic Review for Biotherapeutics Cell Line Development by Process - Transfection & Selection and Single Cell Cloning Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2021 and % CAGR
  • Table 49: Rest of World 16-Year Perspective for Biotherapeutics Cell Line Development by Process - Percentage Breakdown of Value Sales for Transfection & Selection and Single Cell Cloning for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AGC Biologics
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • EMD Millipore Corporation
  • Lonza Group Ltd.
  • MilliporeSigma
  • ProBioGen AG
  • Selexis SA
  • Sony Biotechnology Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.